In ACLU v. Myriad, It's Scientific Accuracy, 0, and Wild Speculation, 1 | GenomeWeb

Unless you've been living under a sequencer, you already know that the ACLU v. Myriad gene patent hearings began yesterday. Daily Scan was there for the circus, held in a standing-room-only courtroom in downtown New York. The ACLU attorneys spent much of their time arguing that isolated DNA was not "markedly different" from native DNA, and therefore not eligible for patent protection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.